{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:14:43Z","timestamp":1783329283059,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007922039"],"award-info":[{"award-number":["Z221100007922039"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201228","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:40:40Z","timestamp":1778197240000},"page":"201228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapidly evolved PD-1 for enhance receptor and checkpoint inhibitor in immunotherapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Xiaowei","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8207-0568","authenticated-orcid":false,"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201228_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201228_bib2","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201228_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201228_bib4","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201228_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201228_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-2478(02)00088-3","article-title":"Microanatomical localization of PD-1 in human tonsils","volume":"83","author":"Iwai","year":"2002","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.omton.2026.201228_bib7","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201228_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201228_bib9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201228_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201228_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201228_bib12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201228_bib13","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201228_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201228_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201228_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201228_bib17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201228_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201228_bib19","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201228_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory CD30+ Lymphoma","volume":"13","author":"Sang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201228_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","article-title":"Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor","volume":"51","author":"Prosser","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201228_bib22","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","article-title":"Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity","volume":"191","author":"Ankri","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201228_bib23","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201228_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-021-00499-z","article-title":"Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins","volume":"11","author":"Blaeschke","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201228_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.omton.2026.201228_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","article-title":"CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies","volume":"14","author":"Liang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201228_bib27","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/s41467-022-33793-w","article-title":"Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis","volume":"13","author":"Qin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201228_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081998","article-title":"T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity","volume":"14","author":"Sailer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201228_bib29","article-title":"Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer","volume":"6","author":"Wan","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201228_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/srep35297","article-title":"High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1","volume":"6","author":"Horita","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201228_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrg3927","article-title":"Methods for the directed evolution of proteins","volume":"16","author":"Packer","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omton.2026.201228_bib32","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.89.12.5467","article-title":"Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells","volume":"89","author":"Rice","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201228_bib33","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1073\/pnas.91.22.10747","article-title":"DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution","volume":"91","author":"Stemmer","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201228_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nbt0697-553","article-title":"Yeast surface display for screening combinatorial polypeptide libraries","volume":"15","author":"Boder","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201228_bib35","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201228_bib36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:17:55Z","timestamp":1783325875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926001049"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201228","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapidly evolved PD-1 for enhance receptor and checkpoint inhibitor in immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201228"}}